RTTNews 汇总多只生物医药股盘中上涨，核心信息多为已披露旧催化或低增量进展

Today's top gainers in the biotech and healthcare space include Tenax Therapeutics, following a sharp rebound despite its recent Phase 3 trial setback; Kura Oncology, on continued Komzifti adoption; Anavex Life Sciences, after returning to profitability; Immatics, following a $150 million offering; and RenovoRx, after positive targeted drug-delivery data, among others.
Read on... TENX Rises Over 27% In Premarket Despite Phase 3 Trial Setback
Tenax Therapeutics (TENX) gained 26.2% in premarket trading despite its recent Phase 3 LEVEL trial of TNX-103 failing to meet its primary and key secondary endpoints in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
The oral levosimendan candidate did not significantly improve 6-minute walk distance or Kansas City Cardiomyopathy Questionnaire total symptom score versus placebo at Week 12.
However, prespecified analyses showed a 49% greater reduction in NT-proBNP and a 3.5 mmHg reduction in right ventricular systolic pressure compared with placebo.
Patients with baseline 6-minute walk distance below 333 meters showed a 26.3-meter improvement versus placebo, suggesting a potentially greater benefit in patients with more severe disease.
Tenax plans to request a Type C meeting with the FDA to discuss an enriched study population and revisions to the registrational development program for TNX-103.
TENX shares are currently trading at $2.36, up 27.80%.
TherapeuticsMD Reports Q2 Revenue Decline; Continues Strategic Review
TherapeuticsMD (TXMD) reported second-quarter 2026 results showing declines in license revenue and net income from continuing operations compared with the prior-year quarter.
License revenue fell to $0.86 million from $0.95 million in Q2 2025, primarily due to changes in sales of licensed products under the Mayne License Agreement.
Net income from continuing operations declined to $0.16 million from $0.55 million a year earlier, while operating expenses increased slightly to $1.69 million from $1.65 million.
Following the quarter, TherapeuticsMD became eligible for a CAD 0.50 million, or approximately $0.36 million, milestone payment tied to IMVEXXY sales, which it expects to recognize in Q3 2026.
The company ended the quarter with $9.2 million in cash and continues to evaluate potential strategic alternatives, including an acquisition, merger, business combination or asset sale.
TXMD shares are currently trading at $2.28, up 10.70%.
Kura Oncology Gains As Komzifti Builds Early Momentum In AML
Kura Oncology (KURA) is gaining attention as its menin inhibitor Komzifti continues to show strong early commercial adoption in relapsed or refractory NPM1-mutated acute myeloid leukemia (AML).
Komzifti generated $9.1 million in net product revenue in the second quarter of 2026, up from $5.8 million in Q1 2026 and $2.1 million in Q4 2025, its first partial quarter following the November 2025 FDA approval.
The company recorded approximately 115 new patient starts in Q2, representing a 35% increase from the prior quarter and supporting continued physician adoption.
Komzifti is also being evaluated in multiple Phase 3 and earlier-stage trials, including combination studies with intensive chemotherapy, venetoclax/azacitidine and other AML therapies.
Kura expects several clinical updates in the second half of 2026, including data from KOMET-007, KOMET-008 and KOMET-001 that could help expand Komzifti's potential across newly diagnosed and relapsed/refractory AML.
As of June 30, 2026, Kura had $519.0 million in cash, cash equivalents and short-term investments. Including $180 million in anticipated collaboration payments from Kyowa Kirin, the company expects funding to support operations through 2028.
KURA shares are currently trading at $13.66, up 10.38%.
Anavex Returns To Profit In Q3 2026; Advances Blarcamesine Across CNS Indications
Anavex Life Sciences Corp. (AVXL) reported third-quarter fiscal 2026 results, returning to profitability while advancing its lead CNS candidate blarcamesine across Alzheimer's disease, Rett syndrome and Fragile X syndrome.
Anavex posted net income of $7.8 million, or $0.08 per share, compared with a net loss of $13.2 million, or $0.16 per share, in Q3 2025.
The return to profit was primarily driven by reversals of stock-based compensation expenses following executive departures.
General and administrative expenses reflected a $2.0 million recovery, compared with $4.5 million in the prior-year quarter, while R&D expenses reflected a $4.7 million recovery versus $10.0 million in Q3 2025.
The company held $118.3 million in cash and cash equivalents at quarter-end, providing funding into mid-to-late fiscal 2028.
Anavex submitted completed Alzheimer's trial data to the FDA and is preparing for Phase 3 discussions. Its Phase 3 adult Rett syndrome study is progressing, with a request to include pediatric patients under FDA review.
The company also plans to submit an IND for Fragile X syndrome in September.
AVXL shares are currently trading at $3.54, up 14.98%.
Immatics Announces $150M Offering; Shares Rise
Immatics N.V. (IMTX) gained nearly 7% after announcing a $150 million underwritten offering to fund its precision oncology pipeline and corporate activities.
The company agreed to sell 12.95 million ordinary shares at $8.69 per share, along with pre-funded warrants to purchase 4.32 million shares at $8.689 per warrant.
Immatics expects gross proceeds of approximately $150 million before underwriting discounts and offering expenses. The offering is expected to close on August 26, 2026.
The company has also granted underwriters a 30-day option to purchase up to an additional 2.59 million shares at the public offering price, less underwriting discounts.
Immatics is advancing a broad PRAME-focused oncology franchise spanning TCR T-cell therapies and TCR bispecifics across multiple cancer indications.
IMTX shares are currently trading at $9.28, up 6.78%.
RenovoRx Shares Rise After TAMP Data Supports Targeted Drug Delivery In Pancreatic Cancer
RenovoRx, Inc. (RNXT) gained more than 15% after publishing peer-reviewed pharmacokinetic and pharmacodynamic data supporting its TAMP targeted drug-delivery platform in locally advanced pancreatic cancer.
The Phase 3 TIGeR-PaC sub-study showed approximately 51% local extraction of intra-arterially delivered gemcitabine before entering systemic circulation, resulting in significantly lower systemic drug exposure than intravenous administration.
The study also found a statistically significant correlation between higher levels of gemcitabine metabolite dFdU and greater reductions in the CA 19-9 tumor marker, providing an early pharmacodynamic signal of potential tumor response.
RenovoRx recently completed enrollment in the Phase 3 TIGeR-PaC trial, with trial completion expected in the first half of 2027 and topline data anticipated in the second half of 2027.
The company also regained compliance with Nasdaq's minimum bid price requirement after its shares closed at $1.00 or higher for 10 consecutive business days from August 6 through August 19, 2026.
RenovoRx reported record quarterly RenovoCath revenue of $0.91 million in Q2 2026 and continues to expand commercialization of its FDA-cleared drug-delivery device.
RNXT shares are currently trading at $1.45, up 16.40%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.